|
|
|
News For HOLX From The Last 14 Days Check below for free stories on HOLX the last two weeks. |
|
|
| June 13, 2013 | | 09:38 EDT |  | HOLX | Hologic estimates lowered below the Street at SunTrust
SunTrust lowered Hologic estimates below the Street due to 3D Tomo adoption concerns following cautious survey results. Share are Reduce rated. | | | June 6, 2013 | | 15:11 EDT |  | HOLX | QIAGEN affirms FY13 view after Quest Diagnostics, Hologic strike deal
QIAGEN (QGEN) said its full-year earnings view will not be changed following an announcement that Quest Diagnostics (DGX) and Hologic (HOLX) reached a supply agreement. WHAT'S NEW: Earlier today, Quest Diagnostics and Hologic announced a non-exclusive agreement for Quest to more broadly offer Hologic's APTIMA family of testing products. Hologic's APTIMA line includes FDA-approved or cleared assays for HPV, HPV genotyping, chlamydia, gonorrhea and trichomonas vaginalis. WHAT'S NOTABLE: Following the announcement, QIAGEN, which competes with Hologic in the diagnostic product space, said that a "U.S. reference laboratory customer" of its products made public a deal to consolidate the purchase of products used for women's health diagnostics with a competitor supplier. QIAGEN said the customer would continue to offer its HPV-related products as well. QIAGEN said that it saw no need to revise its full-year 2013 guidance based on the development. The company also noted that sales related to this development represent less than 2% of the company's anticipated 2014 sales, and HPV screening in the U.S. is expected to represent less than 10% of the company's 2014 total net sales. PRICE ACTION: Hologic advanced following news of its agreement with Quest, and its shares are up over 2% in afternoon trade. QIAGEN shares are off their best levels, but still higher by about 0.5%. | | | 13:08 EDT | | HOLX | Quest Diagnostics, Hologic in strategic alliance for women's health
 Subscribe for More Information | |
|
|
|
|
|
|
